R&D

New drug candidate for the treatment of COVID-19

Researchers from the University of Kent, the Goethe-University in Frankfurt am Main (Germany), and the Hannover Medical School (Germany) have identified a drug with the potential to provide a treatment for COVID-19.

The international team led by Professor Martin Michaelis, Dr Mark Wass (both School of Biosciences, University of Kent), and Professor Jindrich Cinatl (Institute of Medical Virology, Goethe-University) found that

Remdesivir for COVID-19: FDA approved but still unproven

The United States has become the epicenter of the world in the ever increasing pandemic of COVID-19. While public health prevention strategies of social distancing, crowd avoidance, masking and frequent hand washing are of proven benefit, effective drug therapies for treatment are sparse. Not surprisingly, remdesivir has attracted worldwide attention, first receiving an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) and especially with U.S. President Donald Trump taking the drug for COVID-19 earlier this month.

COVID-19 containment shaped by strength, duration of natural, vaccine-induced immunity

"Much of the discussion so far related to the future trajectory of COVID-19 has rightly been focused on the effects of seasonality and non-pharmaceutical interventions [NPIs], such as mask-wearing and physical distancing," said co-first author Chadi Saad-Roy, a Ph.D. candidate in Princeton's Lewis-Sigler Institute for Integrative Genomics.

Oxford COVID-19 vaccine follows its programmed genetic instructions, independent analysis finds

The AstraZeneca Oxford COVID-19 vaccine (ChAdOx1 nCoV-19 and also known as AZD1222) now undergoing Phase III clinical trials, has already undergone rigorous testing to ensure the highest standards of quality and safety. Now a team at Bristol University has used recently developed techniques to further validate that the vaccine accurately follows the genetic instructions programmed into it by the Oxford team.

Scientists identify common vulnerabilities across SARS-CoV-2, SARS-CoV-1 and MERS coronaviruses

In a study published online in Science, an international team of almost 200 researchers from 14 leading institutions in six countries, including France with the Institut Pasteur and CNRS, studied the three lethal coronaviruses SARS-CoV-2, SARS-CoV-1 and MERS-CoV in order to identify commonly hijacked cellular pathways and detect promising targets for broad coronavirus inhibition. In addition,

World Bank approves $12 billion for COVID-19 vaccines

The World Bank's Board of Executive Directors today approved an envelope of $12 billion for developing countries to finance the purchase and distribution of COVID-19 vaccines, tests, and treatments for their citizens.

The financing, which aims to support vaccination of up to a billion people, is part of an overall World Bank Group (WBG) package of up to $160 billion through June 2021 to help developing countries fight the COVID-19 pandemic.

Research & Development

New drug candidate for the treatment of COVID-19

Remdesivir for COVID-19: FDA approved but still unproven

COVID-19 containment shaped by strength, duration of natural, vaccine-induced immunity

Oxford COVID-19 vaccine follows its programmed genetic instructions, independent analysis finds

Scientists identify common vulnerabilities across SARS-CoV-2, SARS-CoV-1 and MERS coronaviruses

Popular COVID-19 conspiracies linked to vaccine 'hesitancy'

World Bank approves $12 billion for COVID-19 vaccines

More Pharma News ...